SWOG clinical trial number
SWOG-9000

Biomarkers of Colorectal Cancer Prognosis

Closed
Phase
Accrual
67%
Published
Abbreviated Title
Biomarkers of Colorectal Cancer Prognosis
Activated
02/15/1991
Closed
09/15/1993

Research committees

Gastrointestinal Cancer

Publication Information Expand/Collapse

1998

Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group study.

DJ Ahnen;P Feigl;G Quan;C Fenoglio-Preiser;LC Lovato;PA Bunn Jr;G Stemmermann;JD Wells;JS Macdonald;FL Meyskens Jr Cancer Research 58:1149-1158

1996

K-ras mutation and p53 overexpression but not ploidy status predict the clinical behavior of colon cancer.

O Gang;D Ahnen;C Fenoglio-Preiser;L Loll;P Bunn;P Feigl Gastroenterology 110(4):A516

Other Clinical Trials

SWOG Clinical Trial Number
S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase
SWOG Clinical Trial Number
S2107

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
100%
Open
Phase